Dona (glucosamine sulfate) powder for oral use 1500 mg. sackets №20

$10.20

Manufacturer: France

For relief of symptoms in mild to moderate osteoarthritis of the knee.

Category:

Description

Dona sackets Storage:

active substance: 1 sachet contains crystalline glucosamine sulfate 1884 mg, equivalent to 1500 mg glucosamine sulfate and sodium chloride 384 mg;

Dona sackets Excipients:

aspartame (E 951), sorbitol (E 420), anhydrous citric acid, macrogol 4000.

Dona sackets Dosage form.

Powder for oral solution.

Main physical and chemical properties:

white crystalline powder, odorless.

Pharmacotherapeutic group.

Nonsteroidal anti-inflammatory and anti-rheumatic drugs. ATX code M01A X05.

Pharmacological properties.

Pharmacodynamics.

The active ingredient is a salt of the amino monosaccharide glucosamine sulfate, which is present in the human body and is used together with sulfates for the biosynthesis of hyaluronic acid synovial fluid and glycosaminoglycans of the main substance of articular cartilage.

The mechanism of action of glucosamine sulfate is the stimulation of the synthesis of glycosaminoglycans and, accordingly, joint proteoglycans. In addition, glucosamine exhibits anti-inflammatory properties, slows down the degradation of articular cartilage mainly due to its metabolic activities, the ability to inhibit the activity of interleukin 1 (IL-1), which, on the one hand, contributes to the symptoms of osteoarthritis, and on the other – delays structural joint disorders, as evidenced by long-term clinical trials.

The effectiveness of glucosamine sulfate against osteoarthritis is obvious in 2-3 weeks from the start of treatment.

The results of clinical studies of daily continuous treatment for 3 years indicate a progressive increase in its effectiveness, due to the symptoms and slowing of structural damage to the joints, which is confirmed by X-ray.

Glucosamine sulfate has shown good tolerability. No significant effects of glucosamine sulfate on the cardiovascular, respiratory, autonomic or central nervous system were detected.

Pharmacokinetics.

90% of the dose of glucosamine sulfate is rapidly and completely absorbed from the gastrointestinal tract, passes through biological barriers and penetrates into tissues, mainly articular cartilage. Bioavailability – 26%. The half-life is 68 hours.

Clinical characteristics.

Indication. Treatment of symptoms of osteoarthritis, ie pain and functional limitations.

Contraindication. Hypersensitivity to glucosamine or to any of the excipients; liver and kidney dysfunction in the stage of decompensation, tendency to bleeding. The powder for oral solution contains aspartame and is therefore contraindicated in patients with phenylketonuria. DONA® should not be used in patients with allergies to molluscs, as the active substance is derived from molluscs.

Interaction with other drugs and other types of interactions. Increased action of coumarin anticoagulants was noted. In this regard, in such patients it is advisable to monitor coagulation parameters. Increased gastrointestinal absorption of tetracyclines is possible. The drug is compatible with nonsteroidal anti-inflammatory drugs and glucocorticosteroids.

Features of application. In patients with asthma, the drug should be used with caution, as such patients may be more prone to develop allergic reactions to glucosamine with possible exacerbation of symptoms of their disease.

Powder for oral use contains sorbitol. This pharmaceutical form is not recommended for patients with rare hereditary problems of fructose intolerance.

1 sachet contains 6.6 mmol (151 mg) of sodium. This should be taken into consideration by patients on a controlled sodium diet.

At the beginning of treatment for patients with diabetes it is advisable to monitor blood sugar levels.

Use only under medical supervision in patients with impaired liver and kidney function, with thrombophlebitis.

Use during pregnancy or breastfeeding. There are no data on the use of the drug during pregnancy or breastfeeding, so the use of the drug is contraindicated in this category of patients.

Ability to influence the speed of reaction when driving a car or other machinery. No studies on the effects on the ability to drive and use machines have been performed. Caution should be exercised when driving and performing work that requires attention. In case of drowsiness, fatigue, dizziness or visual impairment, driving or operating other machinery is prohibited.

Method of application and dosage.

Apply internally.

Adult and elderly patients: Dissolve 1 sachet equivalent to 1500 mg of glucosamine sulfate in a glass of water and take once daily, preferably with meals.

Course of treatment: 4-12 weeks or longer (if necessary).

According to the doctor’s prescription, treatment can be repeated 2-3 times a year with an interval of 2 months, as well as in case of recurrence of the disease.

Children.

Do not use in children, as the safety and efficacy of the drug for such patients have not been established.

Overdose.

No cases of overdose were reported. Based on studies of acute t